Figure 4.
SOX11i (Cpd R) treatment reduced the PAX5 and CD19 protein expression and attenuated downstream BCR signaling in MCL. (A) JeKo-1, JeKo-1_IBN-R, and Z-138 cells were incubated with Cpd R for 12 and 24 hours and IBN at indicated concentrations, after which PAX5 and CD19 were monitored by immunoblotting analysis. (B) JeKo-1, JeKo-1_IBN-R, and Z138 cells were treated for 12 hours and then stimulated with 5 μg/mL of IgM for 10 minutes. Whole-cell lysates were analyzed using immunoblotting. (C) JeKo-1 cells were treated for 6 hours with Cpd R (20 μM) and IBN (0.25 μM), followed by washing, transfer to fresh medium, and collection at the indicated time points. Immunoblotting analysis was then performed. β-Actin was assayed to ensure equivalent loading and transfer. Ctrl, DMSO Control.

SOX11i (Cpd R) treatment reduced the PAX5 and CD19 protein expression and attenuated downstream BCR signaling in MCL. (A) JeKo-1, JeKo-1_IBN-R, and Z-138 cells were incubated with Cpd R for 12 and 24 hours and IBN at indicated concentrations, after which PAX5 and CD19 were monitored by immunoblotting analysis. (B) JeKo-1, JeKo-1_IBN-R, and Z138 cells were treated for 12 hours and then stimulated with 5 μg/mL of IgM for 10 minutes. Whole-cell lysates were analyzed using immunoblotting. (C) JeKo-1 cells were treated for 6 hours with Cpd R (20 μM) and IBN (0.25 μM), followed by washing, transfer to fresh medium, and collection at the indicated time points. Immunoblotting analysis was then performed. β-Actin was assayed to ensure equivalent loading and transfer. Ctrl, DMSO Control.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal